191 related articles for article (PubMed ID: 24706696)
1. Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance.
Ng CKY; Weigelt B; A'Hern R; Bidard FC; Lemetre C; Swanton C; Shen R; Reis-Filho JS
Cancer Res; 2014 Jun; 74(11):2946-2961. PubMed ID: 24706696
[TBL] [Abstract][Full Text] [Related]
2. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
4. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers.
Tan SH; Lee SC
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):283-306. PubMed ID: 20163320
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
7. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer.
Lee SC; Xu X; Chng WJ; Watson M; Lim YW; Wong CI; Iau P; Sukri N; Lim SE; Yap HL; Buhari SA; Tan P; Guo J; Chuah B; McLeod HL; Goh BC
Pharmacogenet Genomics; 2009 Nov; 19(11):833-42. PubMed ID: 19809382
[TBL] [Abstract][Full Text] [Related]
8. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
9. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
Barry WT; Kernagis DN; Dressman HK; Griffis RJ; Hunter JD; Olson JA; Marks JR; Ginsburg GS; Marcom PK; Nevins JR; Geradts J; Datto MB
J Clin Oncol; 2010 May; 28(13):2198-206. PubMed ID: 20368555
[TBL] [Abstract][Full Text] [Related]
10. A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.
Hallett RM; Pond G; Hassell JA
BMC Med Genomics; 2012 May; 5():16. PubMed ID: 22578285
[TBL] [Abstract][Full Text] [Related]
11. Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer.
Jiang T; Shi W; Natowicz R; Ononye SN; Wali VB; Kluger Y; Pusztai L; Hatzis C
BMC Genomics; 2014 Oct; 15(1):876. PubMed ID: 25294321
[TBL] [Abstract][Full Text] [Related]
12. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
14. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
15. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
Huang S; Hu P; Lakowski TM
BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
[TBL] [Abstract][Full Text] [Related]
16. Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods.
Azad AKM; Alyami SA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33857297
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
Sotiriou C; Powles TJ; Dowsett M; Jazaeri AA; Feldman AL; Assersohn L; Gadisetti C; Libutti SK; Liu ET
Breast Cancer Res; 2002; 4(3):R3. PubMed ID: 12052255
[TBL] [Abstract][Full Text] [Related]
20. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
